Celularity

12/18/2025

RELEASE: Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision

Celularity has entered into two binding term sheets for a senior secured term loan and a secured convertible note financing with Philip A. Barach, co-founder and former president of DoubleLine Capital LP.

READ THE FULL RELEASE HERE:
https://www.globenewswire.com/news-release/2025/12/18/3208116/0/en/Celularity-Reaches-Binding-Term-Sheets-on-Financing-Transactions-to-Support-Its-Strategic-Vision.html

10/30/2025

Big announcement! We are excited to be part of DefEYE’s focused expansion into the ophthalmic space and to demonstrate the transformative power of placental-derived regenerative biologic solutions. This strategy fits into our objective of accessing new markets for our portfolio of commercial products.

Read the full release here:
https://www.globenewswire.com/news-release/2025/10/30/3177365/0/en/Celularity-and-DefEYE-Inc-Partner-to-Advance-Growth-of-Regenerative-Therapies-in-Eye-Care.html

10/14/2025

Exciting news! Phase 2 clinical trial results published on the safety and efficacy of placenta-derived cells for diabetic foot ulcers complicated by Peripheral Artery Disease.

This is a significant milestone for Celularity, and importantly, for patients battling diabetic foot ulcers complicated by peripheral artery disease, which is a patient population with a critical unmet medical need and limited treatment options.

Read the full release here:

First-in-class regenerative therapy for diabetic foot ulcers complicated by peripheral artery diseaseCelularity PDA-002 achieved durable wound healing with...

09/03/2025

We are pleased to report that we have filed our Form 10-Q quarterly reports for the first and the second quarters 2025. This comes on the heels of the recently announced retirement of all $32.0 million of the Company’s senior secured debt plus $9.6 million in associated unpaid interest.

Read the full release here:

Company on Friday, August 29, 2025, filed quarterly reports on Form 10-Q for the periods ended March 31, 2025, and June 30, 2025, respectively, in accord...

07/09/2025

RELEASE: Celularity & Fountain Life Announce Partnership to Deliver Stem Cell Therapies Under New Florida Law

We applaud Florida’s proactive, data-driven approach to advancing investigational stem cell therapies and improving patient outcomes, for which Fountain Life, a leading science-backed longevity center, powered by AI, is an ideal partner.

Celularity’s ability today to supply clinical-grade, ethically-sourced stem cells ensures ‘Day One’ readiness under the new Florida law to partners like Fountain Life.

Fountain Life

Read the release here:
https://www.globenewswire.com/news-release/2025/07/09/3112554/0/en/Celularity-Fountain-Life-Announce-Partnership-to-Deliver-Stem-Cell-Therapies-Under-New-Florida-Law.html

07/01/2025

Release: Celularity Hails New Florida Law Opening Patient Access to Stem Cell Therapies

As a long-standing leader in the field of ethically sourced stem cell therapies, we applaud Florida’s intention to advance medical treatments and improve patient outcomes with this balanced approach to fostering medical innovation while upholding ethical standards.

Celularity is positioned right now to supply the stem cells necessary to fulfill the objectives of the new Florida law and we look forward to working with Florida physicians to ensure their patients have access to stem cell therapies.

Read the full release here:
https://www.globenewswire.com/news-release/2025/07/01/3108312/0/en/Celularity-Hails-New-Florida-Law-Opening-Patient-Access-to-Stem-Cell-Therapies.html

06/02/2025

Advancing Ocular Surface Reconstruction: Our DDHAM-3L technology, with its unique biological properties, offers a promising platform for delivering patient-specific, iPSC-derived LSCs to restore vision and improve patient outcomes. This also supports broader applications of this biomaterial technology beyond ophthalmology.

Highlights the unique potential of Celularity’s proprietary advanced biomaterial technology as a novel cellular delivery system for ocular surface...

04/14/2025

Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products

Action delays to January 1, 2026, the effective date of a Biden-era Medicare LCD for skin substitute products used to treat diabetic foot ulcers and venous leg ulcers.

Read the full release here:
https://www.globenewswire.com/news-release/2025/04/14/3060835/0/en/Celularity-Welcomes-CMS-Action-on-Medicare-Local-Coverage-Determination-for-Skin-Substitutes-Products.html

04/07/2025

An important publication form our team in Frontiers in Immunology: Senescence, NK Cells, and Cancer.

NK cell-based therapies demonstrate promise not only in treating cancer and viral infections but also a key role in rejuvenating the aging immune system, by eliminating senescent cells.


Read the full release - with link to the publication - here:
https://www.globenewswire.com/news-release/2025/04/07/3056681/0/en/Celularity-Announces-Publication-of-Senescence-NK-cells-and-cancer-navigating-the-crossroads-of-aging-and-disease-in-the-April-4-2025-Issue-of-Frontiers-in-Immunology.html

02/25/2025

Excited to receive FDA Tissue Reference Group recommendation letters on the newest additions to our portfolio of human placental-derived biomaterials! This serves as a further testament to our commitment to innovate in the wound care sector and will further enable us to build on our commercial momentum.
Full story here:
https://www.globenewswire.com/news-release/2025/02/25/3031935/0/en/Celularity-Receives-FDA-Tissue-Reference-Group-Recommendation-Letters-for-its-Natalin-and-Acelagraft-Wound-Care-Products.html

01/24/2025

"One of the most exciting advancements in stem cell therapy is the shift from focusing solely on oncology to exploring how stem cell therapies can address chronic diseases and aging-related conditions like frailty, cognitive decline and immune system failure."

Read the full feature in Drug Target Review's Beyond the Lab Report on the work Celularity is doing in the realm of stem cell therapies. (Found on page 6.)
https://indd.adobe.com/view/d551a70e-1b10-4e44-a2b8-19f7cc1bb252

01/23/2025

Celularity, Inc. is proud to be a member of the MASS Coalition. The MASS Coalition is made up of a group of likeminded business leaders who, together, are working with the new administration to prevent amputation and other complications associated with Diabetes and Cardiovascular disease. Re-evaluating the coverage decisions associated with skin substitutes is the first necessary step in ensuring patients have access to technologies that will assist in their care.

Read the full article here: https://saveourwoundcare.org/media/